# mAbxience opens $40M biosimilar antibody plant in Garín, Argentina

mAbxience, part of Insud Pharma, inaugurated a new biosimilar monoclonal antibody production plant in Garín, Buenos Aires, Argentina. The $40 million facility doubles the company's production capacity and created 50 new jobs.

- Type: New facility
- Announced: 2020-02-21
- Where: Garín, Buenos Aires, Argentina
- Value: $40.0M
- Jobs: 50
- Starts operating: 21 Feb 2020
- Status: completed
- Products: biosimilar monoclonal antibodies
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [mAbxience](https://endata.com/companies/41412.md)
- [Insud Pharma](https://endata.com/companies/45428.md) (partner)

## Sources

- [insudpharma.com](https://www.insudpharma.com/new/mabxience-inaugura-una-nueva-planta-de-anticuerpos-monoclonales-biosimilares-en-argentina/), 2020-02-21: "mAbxience inauguró una nueva planta de producción de anticuerpos monoclonales biosimilares en Garín, provincia de Buenos Aires (Argentina)."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.